Why You Should Not Worry About Eli Lilly (LLY) and Company's Foundayo Treatment Prospects [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
The bullishness underscores the research firm's confidence that the company is facing manageable post-marketing study requirements for the Foundayo treatment. Why You Should Not Worry About Eli Lilly (LLY) and Company's Foundayo Treatment Prospects Following the US Food and Drug Administration approval of Foundayo on April 1 for chronic weight management, Eli Lilly is required to conduct post-marketing studies. The studies are to evaluate serious risks, including liver injury and gastric issues associated with the drug. Eli Lilly is already conducting the Phase 3 ACHIEVE-4 trial of daily Foundayo in patients with type 2 diabetes who are obese. BMO Capital does not expect the studies to have any meaningful impact on the drug's competitive edge. In addition, the post-market studies requirements are not an underlying risk to Eli Lily's program but reflect the FDA's conservatism. Foundayo is a small-molecule drug that is easier and faster to produce, expected to give Eli Lilly a s
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation TrialGlobeNewswire
- 3 Healthcare Stocks With the Most Durable Competitive Moats [Yahoo! Finance]Yahoo! Finance
- 3 Healthcare Stocks With the Most Durable Competitive Moats [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Is Eli Lilly Stock Actually ... Cheap? The Surprising Math Behind Its 2026 Valuation. [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Biotech Investor Alex Karnal: GLP-1 Drugs Signal ‘Trillion-Dollar Revolution' in Public Health [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 4/21/26 - Form 4
- 4/21/26 - Form 4
- 4/21/26 - Form 4
- LLY's page on the SEC website